Home » IVT RNA Production Services » Catalog IVT mRNA, circRNA, saRNA, LNP products » CBEmax mRNA (Cap1, m1Ψ)

CBEmax mRNA (Cap1, m1Ψ)

RP-A00002
$300.00

Ask us a question
Description

Cytosine base editors (CBEs) system is constructed by fusing an artificially evolved cytosine deaminase to a mutated Cas9 that is a single-strand DNA nickase, can precisely and permanently convert C·G to T·A with the guidance of a target-specific guide RNA (gRNA) without creating a double-strand DNA break and without requiring an exogenous DNA repair donor. This mRNA is human codon optimized CBE4max SpCas9 variant named SpG, with sequence originally from Walton et al Science 2020 Apr 17; 368(6488):290-296.  
 
This mRNA features: 
- A Cap 1 structure with high capping efficiency 
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response 
- GenScript’s patented UTR to enhance translation 
- A 100A poly(A) tail to mimic natural mature mRNA
Properties
Form Liquid
Concentration 1mg/mL
Full mRNA length 5831nt
Full mRNA Molecular Weight 1899231
Storage Store at -20°C for short term (<3 months), store at -80°C for long term.
Storage buffer 1mM Sodium citrate, pH6.5

Quality Control Specifications
Appearance Clear and free of foreign particles
RNA Length Expected size band detected
RNA Content Target ± 5%
Integrity ≥ 75%
OD260/OD280 1.70 ~ 2.30
Capping Efficiency ≥ 90%
Endotoxin < 10 EU/mg
pH Target ± 0.5

Applications
Transfect a total of 0.5-1.5 µg of CBEmax mRNA and sgRNA per well (recommended molar ratio 1:10), using a transfection reagent, electroporation, or LNP encapsulation in a 24-well plate (~2 × 10⁵ cells/well). Assess genome editing efficiency 48-72 hours post-transfection via sequencing.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.